KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

Guangwen Yuan, Ge Lou, Jundong Li, Mei Xu, Xiaowei Liu, Danbo Wang, Keqiang Zhang, Tao Zhu, Xiumin Li, Yi Huang, Wei Duan, Ke Wang, Qi Zhou, Guiling Li, Chen Yang, Jiajing Zhang, Haolin Sun, Renhong Tang, Qingshui Li, Lingying Wu

Nat Cancer 7(1) 182-193

PMID41514054
PMCIDPMC12858396
DOI10.1038/s43018-025-01085-z
发表日期2026-01-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the SCORES study ( NCT04908787 ), women with ovarian cancer that progressed within 6 months after completing platinum-based therapy were randomized (2:1) to receive suvemcitug (1.5 mg kg-1), an antibody to vascular endothelial growth factor or placebo every 2 weeks, with chemotherapy (paclitaxel, topotecan or PEGylated liposomal doxorubicin). The primary endpoint was progression-free survival (PFS). The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, disease control rate, duration of response, quality of life, safety, pharmacokinetics and antidrug antibodies. Between June 5, 2021 and October 11, 2024, 421 participants were randomized (49.4% and 49.4% previously exposed to antiangiogenic agents and poly(ADP-ribose) polymerase inhibitors, respectively). Median PFS was 5.5 and 2.7 months in the suvemcitug and placebo arms, respectively (hazard ratio: 0.46, 95% confidence interval (CI): 0.35-0.60, P < 0.001), meeting the primary endpoint. Median OS was 15.3 versus 14.0 months, respectively (hazard ratio: 0.77, 95% CI: 0.60-0.99, P = 0.03). Decreased neutrophil count and decreased white blood cell count were the most common grade ≥3 treatment-emergent adverse events (TEAEs) in the suvemcitug arm. No suvemcitug-related grade 5 TEAE occurred. In conclusion, the addition of suvemcitug to chemotherapy significantly improved PFS and OS, with tolerable toxicities.

KM 提取结果

3 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2. Survival outcomes. a , Kaplan–Meier curve of PFS at the first efficacy analysis in the full analysis set assessed by BIRC per RECIST (v.1.1). Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. P < 0.0001. b , Kaplan–Meier curve of OS in the full analysis set at the final analysis. Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. P = 0.03. PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy. Source data

A

PFS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure2 个面板

Extended Data Fig. 1

Extended Data Fig. 1. Subgroup analyses of progression-free survival based on prior exposure to PARP inhibitors. a , patients who were PARP inhibitor naïve. Number of patients: 145 and 70 in the suvemcitug and placebo groups, respectively. P = 0.0004 . b , patients who had received prior PARP inhibitor therapy. Number of patients: 136 and 70 in the suvemcitug and placebo groups, respectively. P < 0.0001 . Source data

A

Progression Free Survival

Extended Data Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression Free Survival

Extended Data Fig. 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
KM Figure1 个面板

Extended Data Fig. 2

Extended Data Fig. 2. Supplementary and subgroup analyses of overall survival. a , Kaplan-Meier curve of overall survival of patients without subsequent antitumor therapy. Number of patients: 281 and 140 in the suvemcitug and placebo groups, respectively. P = 0.01 . Hypothetical estimands strategy was used for the supplemental analysis. 95% CI, 95% confidence interval; HR, hazard ratio; PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy. b , Forest plots for overall survival. Shown are the results of prespecified subgroup analyses of overall survival at the final analysis in the full analysis set. The hazard ratio (HR) for progression or death that is reported for all the randomized patients was based on a Cox proportional-hazards model. Source data

A

Overall Survival

Extended Data Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:off origin start曲线 2:off origin start
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Participant flow in the SCORES trial. a Participants were randomized in a 2:1 ratio and stratified according to platinum-refractory status (yes versus no), number of prior systemic therapies (one versus two), chemotherapeutic agent (paclitaxel versus PEGylated liposomal doxorubicin versus topotecan) and prior antiangiogenic therapy (yes versus no). More information is provided in the Table 1 footnotes. For the safety analysis, one participant who was randomized but did not receive planned treatment was excluded.
非 KM Figure
Fig. 3Fig. 3. Forest plots for PFS per BIRC. Shown are the results of prespecified and unplanned post hoc analysis for previous received PARP (yes, no) subgroup analyses in the full analysis set. The HR for progression or death was based on Cox proportional-hazards regression analysis for all randomized participants. No stratification was used in the forest plots. Source data
非 KM Figure
Fig. 4Fig. 4. Treatment responses. Waterfall plots of the best percentage changes for the sum of target lesion diameters are shown for individual participants with platinum-refractory or resistant recurrent OC assessed by BIRC per RECIST (v.1.1). Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. The lower dashed line indicates a 30% reduction and the upper dashed line represents a 20% increase in the target lesion size. The ORR was defined as the proportion of participants in the full analysis set with a complete response or a partial response. Source data
非 KM Figure
Extended Data Fig. 3Extended Data Fig. 3. EORTC QLQ-C30 change from baseline over time. a , global health scale, functional scales. b , physical function. c , role function. d , emotional function. e , cognitive function. f , social function and symptom scales. g , fatigue. h . nausea and vomiting. i , pain. j , dyspnea. k , insomnia. l , appetite loss. m , constipation. n , diarrhea. o , financial difficulties. Scores range from 0 to 100; a higher score represents higher (‘better’) global health status/overall quality of life and function or symptoms. EORTC, European Organization for Research and Treatment of Cancer; GHS, global health scale; QLQ-C30, Quality of Life Core 30 questionnaire; QoL, quality of life; SE, standard error; PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy. Source data
非 KM Figure
Extended Data Fig. 4Extended Data Fig. 4. Mean changes in EORTC QLQ Ovarian Cancer Module (EORTC QLQ-OV28) QoL parameters. a , QLQ-OV28 abdominal/gastrointestinal symptoms. b , peripheral neuropathy. c , hormonal. d , body image. e , attitudes toward disease. f , other chemotherapy-related adverse effects. g , sexual function. Scores range from 0 to 100; a higher score represents better function or symptoms. EORTC, European Organization for Research and Treatment of Cancer; QoL, quality of life; SE, standard error; PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy. Source data
非 KM Figure